Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 23;40(8):111249.
doi: 10.1016/j.celrep.2022.111249.

Disruption of nuclear envelope integrity as a possible initiating event in tauopathies

Affiliations
Free article

Disruption of nuclear envelope integrity as a possible initiating event in tauopathies

Marine Prissette et al. Cell Rep. .
Free article

Abstract

The microtubule-associated protein tau is an abundant component of neurons of the central nervous system. In Alzheimer's disease and other neurodegenerative tauopathies, tau is found hyperphosphorylated and aggregated in neurofibrillary tangles. To obtain a better understanding of the cellular perturbations that initiate tau pathogenesis, we performed a CRISPR-Cas9 screen for genetic modifiers that enhance tau aggregation. This initial screen yielded three genes, BANF1, ANKLE2, and PPP2CA, whose inactivation promotes the accumulation of tau in a phosphorylated and insoluble form. In a complementary screen, we identified three additional genes, LEMD2, LEMD3, and CHMP7, that, when overexpressed, provide protection against tau aggregation. The proteins encoded by the identified genes are mechanistically linked and recognized for their roles in the maintenance and repair of the nuclear envelope. These results implicate the disruption of nuclear envelope integrity as a possible initiating event in tauopathies and reveal targets for therapeutic intervention.

Keywords: ASO; CP: Neuroscience; CRISPR genetic screen; LEM domain proteins; microtubule associate protein tau; neurodegeneration; nuclear envelope integrity; nuclear envelope rupture; tau aggregation; tau phosphorylation; tauopathy.

PubMed Disclaimer

Conflict of interest statement

Declarations of interest The authors are employees of and shareholders in Regeneron Pharmaceuticals (“Regeneron”). Regeneron has filed patent applications around the described work. The authors declare no competing interests.

Publication types

MeSH terms

LinkOut - more resources